SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

George T. Budd, William E. Barlow, Halle C F Moore, Timothy James Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, Jonathan K. Cho, Kristine J. Rinn, Kathy S. Albain, Helen K. Chew, Gary V. Burton, Timothy D. Moore, Gordan Srkalovic, Bradley A. McGregor, Lawrence E. Flaherty, Robert B. Livingston, Danika L. Lew, Julie R. Gralow, Gabriel N. Hortobagyi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods: A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α =.05 Overall survival (OS) was a secondary outcome Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P =.024; OS P = 010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = 040) but not in DFS (P =.11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2) -negative tumors (P =.067), with no differences seen with hormone receptor-positive/HER2-negative (P =.90) or HER2-positive tumors (P =.40) Conclusion: Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor-negative/HER2-negative tumors.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
JournalJournal of Clinical Oncology
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Appointments and Schedules
Breast Neoplasms
Drug Therapy
Disease-Free Survival
Survival
Hormones
Random Allocation
Paclitaxel
Doxorubicin
Cyclophosphamide
Medical Futility
Neoplasms
Anthracyclines
varespladib methyl
human ERBB2 protein
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

SWOG S0221 : A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. / Budd, George T.; Barlow, William E.; Moore, Halle C F; Hobday, Timothy James; Stewart, James A.; Isaacs, Claudine; Salim, Muhammad; Cho, Jonathan K.; Rinn, Kristine J.; Albain, Kathy S.; Chew, Helen K.; Burton, Gary V.; Moore, Timothy D.; Srkalovic, Gordan; McGregor, Bradley A.; Flaherty, Lawrence E.; Livingston, Robert B.; Lew, Danika L.; Gralow, Julie R.; Hortobagyi, Gabriel N.

In: Journal of Clinical Oncology, Vol. 33, No. 1, 01.01.2015, p. 58-64.

Research output: Contribution to journalArticle

Budd, GT, Barlow, WE, Moore, HCF, Hobday, TJ, Stewart, JA, Isaacs, C, Salim, M, Cho, JK, Rinn, KJ, Albain, KS, Chew, HK, Burton, GV, Moore, TD, Srkalovic, G, McGregor, BA, Flaherty, LE, Livingston, RB, Lew, DL, Gralow, JR & Hortobagyi, GN 2015, 'SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer', Journal of Clinical Oncology, vol. 33, no. 1, pp. 58-64. https://doi.org/10.1200/JCO.2014.56.3296
Budd, George T. ; Barlow, William E. ; Moore, Halle C F ; Hobday, Timothy James ; Stewart, James A. ; Isaacs, Claudine ; Salim, Muhammad ; Cho, Jonathan K. ; Rinn, Kristine J. ; Albain, Kathy S. ; Chew, Helen K. ; Burton, Gary V. ; Moore, Timothy D. ; Srkalovic, Gordan ; McGregor, Bradley A. ; Flaherty, Lawrence E. ; Livingston, Robert B. ; Lew, Danika L. ; Gralow, Julie R. ; Hortobagyi, Gabriel N. / SWOG S0221 : A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 1. pp. 58-64.
@article{f3614e3afe9f4c2f8e5964050e60e6c1,
title = "SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer",
abstract = "Purpose: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods: A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90{\%} power with two-sided α =.05 Overall survival (OS) was a secondary outcome Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P =.024; OS P = 010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = 040) but not in DFS (P =.11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2) -negative tumors (P =.067), with no differences seen with hormone receptor-positive/HER2-negative (P =.90) or HER2-positive tumors (P =.40) Conclusion: Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor-negative/HER2-negative tumors.",
author = "Budd, {George T.} and Barlow, {William E.} and Moore, {Halle C F} and Hobday, {Timothy James} and Stewart, {James A.} and Claudine Isaacs and Muhammad Salim and Cho, {Jonathan K.} and Rinn, {Kristine J.} and Albain, {Kathy S.} and Chew, {Helen K.} and Burton, {Gary V.} and Moore, {Timothy D.} and Gordan Srkalovic and McGregor, {Bradley A.} and Flaherty, {Lawrence E.} and Livingston, {Robert B.} and Lew, {Danika L.} and Gralow, {Julie R.} and Hortobagyi, {Gabriel N.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1200/JCO.2014.56.3296",
language = "English (US)",
volume = "33",
pages = "58--64",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - SWOG S0221

T2 - A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

AU - Budd, George T.

AU - Barlow, William E.

AU - Moore, Halle C F

AU - Hobday, Timothy James

AU - Stewart, James A.

AU - Isaacs, Claudine

AU - Salim, Muhammad

AU - Cho, Jonathan K.

AU - Rinn, Kristine J.

AU - Albain, Kathy S.

AU - Chew, Helen K.

AU - Burton, Gary V.

AU - Moore, Timothy D.

AU - Srkalovic, Gordan

AU - McGregor, Bradley A.

AU - Flaherty, Lawrence E.

AU - Livingston, Robert B.

AU - Lew, Danika L.

AU - Gralow, Julie R.

AU - Hortobagyi, Gabriel N.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods: A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α =.05 Overall survival (OS) was a secondary outcome Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P =.024; OS P = 010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = 040) but not in DFS (P =.11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2) -negative tumors (P =.067), with no differences seen with hormone receptor-positive/HER2-negative (P =.90) or HER2-positive tumors (P =.40) Conclusion: Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor-negative/HER2-negative tumors.

AB - Purpose: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods: A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α =.05 Overall survival (OS) was a secondary outcome Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P =.024; OS P = 010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = 040) but not in DFS (P =.11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2) -negative tumors (P =.067), with no differences seen with hormone receptor-positive/HER2-negative (P =.90) or HER2-positive tumors (P =.40) Conclusion: Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor-negative/HER2-negative tumors.

UR - http://www.scopus.com/inward/record.url?scp=84920576208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920576208&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.56.3296

DO - 10.1200/JCO.2014.56.3296

M3 - Article

C2 - 25422488

AN - SCOPUS:84920576208

VL - 33

SP - 58

EP - 64

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -